Home › Research › Health systems and care delivery
R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25
Arora Paul, Ramagopalan Sreeram V. Journal of comparative effectiveness research, 2026-04-16
Topic: Risk, prevention and care in population studies
In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Paul, A., & Ramagopalan Sreeram, V. (2026). R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25. Journal of comparative effectiveness research. https://doi.org/10.57264/cer-2026-0073
Vancouver
Paul A, Ramagopalan Sreeram V. R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25. Journal of comparative effectiveness research. 2026. doi:10.57264/cer-2026-0073. PMID: 41987656.
BibTeX
@article{paul2026-41987656,
author = {Paul, Arora and Ramagopalan Sreeram, V.},
title = {{R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25}},
journal = {Journal of comparative effectiveness research},
year = {2026},
doi = {10.57264/cer-2026-0073},
pmid = {41987656},
url = {https://doi.org/10.57264/cer-2026-0073}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In this update, we discuss the use of real-world data in the Haute Autorité de Santé assessment of economic evaluations, review how real-world evidence is supporting regulatory approvals in multiple myeloma, and consider lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease for the broader application of target trial emulation.
Why it matters
This round-up discusses real-world evidence in health technology assessment and draws lessons from the failed EVOKE trials of semaglutide in Alzheimer's disease. It reports that those trials failed and offers no evidence of a treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 32/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of comparative effectiveness research) |
| Journal's citation record | 0 / 4 | Journal of Comparative Effectiveness Research: journal h-index 50 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 7.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author Sreeram V Ramagopalan: h-index 2 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Toronto: institution h-index 1,923 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41987656) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 32 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.57264/cer-2026-0073
- PubMed: 41987656
- Original source →
- Free full text: Journal of Comparative Effectiveness Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery
Also in Health systems and care delivery
172 studies in the library are filed under Health systems and care delivery with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Health systems and care delivery hub.